Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Ridgeback Biotherapeutics by Year
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Cost of sales profit-sharing & manufacturing ($M) ($M)
Merck Ridgeback Biotherapeutics: $235M in FY2025, down 57.6% from a year earlier.
Latest, FY2025
235
Period ended Dec 31, 2025
Change on a year earlier
-57.6%
554 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Cost of sales profit-sharing & manufacturing ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 235 | -57.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 554 | -35.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 852 | -72.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 3,038 | +505.2% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 502 | +2,852.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 17 | – | Form 10-K (filed 2023-02-24) ↗ |
Cite this data
StockData. (2026). Merck Ridgeback Biotherapeutics ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-ridgeback-cos
See every metric in the Merck KPI table. Data updated Oct 26, 2026.